Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a landmark study, a multimodal artificial intelligence model derived from digitized histopathology and clinical variables identified men with intermediate-risk disease most likely to benefit from the addition of short-term androgen deprivation therapy to radiotherapy.
“In a landmark study, a multimodal artificial intelligence model derived from digitized histopathology and clinical variables identified men with intermediate-risk disease most likely to benefit from the addition of short-term androgen deprivation therapy to radiotherapy [21].”
From A decision-oriented framework for genomic testing across the prostate cancer continuum (2026) · cites this paper as [21]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredArtificial intelligence-enabled digital pathology biomarkers are advancing from retrospective validation toward prospective implementation studies.
“In parallel, artificial intelligence–enabled digital pathology biomarkers are advancing from retrospective validation toward prospective implementation studies [21, 22].”
From A decision-oriented framework for genomic testing across the prostate cancer continuum (2026) · cites this paper as [21]
The Methods and Discussion describe retrospective validation of an AI biomarker using digitized pathology slides, including slides from patients enrolled in prospective trials. The Discussion calls for further validation, but does not describe prospective implementation studies; participation in a prospective trial does not make this biomarker assessment a prospective implementation study. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Esteva, A., Feng, J., van der Wal, D., Huang, S.-C., Simko, J. P., DeVries, S., Chen, E., Schaeffer, E. M., Morgan, T. M., Sun, Y., et al. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00613-w · Cited by 217 · see citing works
Artificial intelligence predictive model for hormone therapy use in prostate cancer
Spratt, D. E., Tang, S., Sun, Y., Huang, H.-C., Chen, E., Mohamad, O., Armstrong, A. J., Tward, J. D., Nguyen, P. L., Lang, J. M., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300023 · Cited by 153 · see citing works
Ross, A. E., Zhang, J., Huang, H.-C., Yamashita, R., Keim-Malpass, J., Simko, J. P., DeVries, S., Morgan, T. M., Souhami, L., Dobelbower, M. C., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.01.004 · Cited by 35 · see citing works
Flagged first, then by citations
Research works printed but not linked: 12
- [1]Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023; 73(1): 17– 48. doi: 10.3322/caac.21763 36633525 · DOI · Paper page
- [2]Elmehrath AO, Afifi AM, Al-Husseini MJ, Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016. JAMA Network Open. 2021; 4(8): e2119568. doi: 10.1001/jamanetworkopen.2021.19568 34351403 PMC8343467 · DOI
- [3]Herberts C, Wyatt AW, Nguyen PL, Cheng HH. Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair. Am Soc Clin Oncol Educ Book. 2023;(43): e390384. doi: 10.1200/EDBK_390384 37207301 · DOI
- [4]Mateo J, McKay R, Abida W, Accelerating precision medicine in metastatic prostate cancer. Nat Cancer. 2020; 1(11): 1041– 1053. doi: 10.1038/s43018-020-00141-0 34258585 PMC8274325 · DOI
- [5]Phillips R, Shi WY, Deek M, Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncology. 2020; 6(5): 650– 659. doi: 10.1001/jamaoncol.2020.0147 32215577 PMC7225913 · DOI
- [6]Ost P, Reynders D, Decaestecker K, Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. JCO. 2018; 36(5): 446– 453. doi: 10.1200/JCO.2017.75.4853 29240541 · DOI
- [7]Tang C, Sherry AD, Haymaker C, Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncology. 2023; 9(6): 825– 834. doi: 10.1001/jamaoncol.2023.0161 37022702 PMC10080407 · DOI
- [8]Palma DA, Olson R, Harrow S, Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. JCO. 2020; 38(25): 2830– 2838. doi: 10.1200/JCO.20.00818 PMC7460150 32484754 · DOI
- [9]Deek MP, Van der Eecken K, Sutera P, Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol. 2022; 40(29): 3377– 3382. doi: 10.1200/JCO.22.00644 36001857 PMC10166371 · DOI
- [10]Sutera P, Deek MP, Van der Eecken K, WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 2023; 115(5): 1095– 1101. doi: 10.1016/j.ijrobp.2022.12.006 PMC10443895 36708787 · DOI
- [14]Sutera PA, Shetty AC, Hakansson A, Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Annals of Oncology. 2023; 34(7): 605– 614. doi: 10.1016/j.annonc.2023.04.515 37164128 PMC10330666 · DOI
- [15]Dathathri E, Isebia KT, Abali F, Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer. Front Oncol. 2022; 12. doi: 10.3389/fonc.2022.863472 PMC9165750 35669415 · DOI
Cited by
Sorted by citations
A decision-oriented framework for genomic testing across the prostate cancer continuum
Cobran, E. K., Samadder, N. J., Schaid, D. J., Conti, D. V., Haiman, C., Vargas, L., Gionfriddo, M. R., & Tilburt, J. C. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.06.002 · Cited by 1 · see citing works
- Authors
- Wang, J. H., Deek, M. P., Mendes, A. A., Song, Y., Shetty, A., Bazyar, S., Van der Eecken, K., Chen, E., Showalter, T. N., Royce, T. J., Todorovic, T., Huang, H.-C., Houck, S. A., Yamashita, R., Kiess, A. P., Song, D. Y., Lotan, T., DeWeese, T., Marchionni, L., Ren, L., Sawant, A., Simone, N., Berlin, A., Onal, C., Esteva, A., Feng, F. Y., Tran, P. T., Sutera, P., & Ost, P.
- Venue
- Radiotherapy and Oncology
- Publisher
- Elsevier BV
- Published
- 2025-01
- Volume
- 202
- Pages
- 110618
- ISSN
- 0167-8140
- PMC
- PMC11663099
- Cited by
- 24
- References
- 3
- Language
- en
- Licence
- Funders
- US Department of Defense (W81XWH-21\u20131\u20130296)
- National Cancer Institute (1R01CA271540, U54CA273956)
- Prostate Cancer Foundation
- National Institutes of Health
- Movember Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
